AR090219A1 - Anticuerpos humanos frente a toxinas de clostridium difficile - Google Patents

Anticuerpos humanos frente a toxinas de clostridium difficile

Info

Publication number
AR090219A1
AR090219A1 ARP130100670A ARP130100670A AR090219A1 AR 090219 A1 AR090219 A1 AR 090219A1 AR P130100670 A ARP130100670 A AR P130100670A AR P130100670 A ARP130100670 A AR P130100670A AR 090219 A1 AR090219 A1 AR 090219A1
Authority
AR
Argentina
Prior art keywords
antibodies
difficile
toxin
human antibodies
clostridium difficile
Prior art date
Application number
ARP130100670A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR090219A1 publication Critical patent/AR090219A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Anticuerpos totalmente humanos que se unen a la toxina A o a la toxina B de Clostridium difficile, o tanto a la toxina A como a la toxina B, composiciones que comprenden los anticuerpos y métodos de uso. Los anticuerpos son útiles para neutralizar las toxinas de C. difficile, proporcionando así un medio para tratar la enfermedad y síntomas asociados con una infección por C. difficile, incluyendo el tratamiento de diarrea, o colitis pseudomembranosa causada por C. difficile. Los anticuerpos también pueden prevenir la gravedad y/o duración de la enfermedad primaria, o pueden prevenir el número, duración, y/o la gravedad de recurrencias, o recaídas de la enfermedad atribuidas a la presencia de C. difficiIe. Los anticuerpos también pueden ser útiles para el diagnóstico de una infección por C. difficile. Acido nucleico, vector y célula huésped.
ARP130100670A 2012-03-02 2013-03-01 Anticuerpos humanos frente a toxinas de clostridium difficile AR090219A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605914P 2012-03-02 2012-03-02
US201261608255P 2012-03-08 2012-03-08
US201261717404P 2012-10-23 2012-10-23

Publications (1)

Publication Number Publication Date
AR090219A1 true AR090219A1 (es) 2014-10-29

Family

ID=47844536

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100670A AR090219A1 (es) 2012-03-02 2013-03-01 Anticuerpos humanos frente a toxinas de clostridium difficile

Country Status (18)

Country Link
US (2) US9399674B2 (es)
EP (1) EP2820044A1 (es)
JP (2) JP2015509962A (es)
KR (1) KR20140130709A (es)
CN (2) CN108101983A (es)
AR (1) AR090219A1 (es)
AU (1) AU2016203511A1 (es)
BR (1) BR112014021251A2 (es)
CA (1) CA2863536A1 (es)
HK (1) HK1200463A1 (es)
IL (1) IL233884A0 (es)
MX (1) MX2014010527A (es)
NZ (2) NZ714516A (es)
RU (2) RU2017127772A (es)
SG (2) SG10201610123UA (es)
TW (1) TWI592422B (es)
UY (1) UY34652A (es)
WO (1) WO2013130981A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055817T2 (hu) 2009-07-08 2021-12-28 Kymab Ltd Állatmodellek és terápiás molekulák
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
WO2016131157A1 (en) 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2016168392A1 (en) * 2015-04-15 2016-10-20 Medimmune, Llc Methods for treating clostridium difficile infection and associated disease
US20200377606A1 (en) 2016-04-18 2020-12-03 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
US11299751B2 (en) * 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20210032351A1 (en) * 2017-12-13 2021-02-04 Xdcexplorer (Shanghai) Co., Ltd. Egfrviii antibody and conjugate, and preparation method and use thereof
US11992520B2 (en) 2018-09-18 2024-05-28 Vanderbilt University Human monoclonal antibodies to Staphylococcal aureus Isd proteins and uses thereof
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
WO2021219786A1 (en) 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5224657A (en) 1989-05-23 1993-07-06 Kabushiki Kaisha Toshiba Cryogenic refrigerator
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
ATE390933T1 (de) * 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CN1809591A (zh) * 2003-05-21 2006-07-26 米德列斯公司 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体
RS51908B (en) * 2004-02-06 2012-02-29 University Of Massachusetts CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
EP1833510A4 (en) 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
CN101489584B (zh) * 2006-04-17 2013-05-01 先灵-普劳有限公司 重组减毒梭状芽孢杆菌生物体和疫苗
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007280861B2 (en) * 2006-08-02 2013-02-07 Johannes Gutenberg-Universitat Mainz Medicament for LCT poisoning
US8035027B2 (en) 2006-10-09 2011-10-11 Solexel, Inc. Solar module structures and assembly methods for pyramidal three-dimensional thin-film solar cells
US20110020356A1 (en) 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
AU2009219358A1 (en) 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
JP5740714B2 (ja) 2009-02-20 2015-06-24 ヘルス プロテクション エージェンシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
MX342623B (es) 2009-06-26 2016-10-06 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
EP2480255B1 (en) * 2009-09-23 2017-11-22 Thomas Julius Borody Therapy for chronic enteric infections
US20120282274A1 (en) 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
NZ719253A (en) 2010-02-08 2022-08-26 Regeneron Pharma Common light chain mouse
EP2558493B1 (en) 2010-04-15 2019-09-18 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease

Also Published As

Publication number Publication date
HK1200463A1 (en) 2015-08-07
NZ714516A (en) 2017-06-30
TWI592422B (zh) 2017-07-21
US20160264650A1 (en) 2016-09-15
AU2013203942A1 (en) 2013-09-19
IL233884A0 (en) 2014-09-30
TW201350501A (zh) 2013-12-16
RU2017127772A (ru) 2019-02-04
US9399674B2 (en) 2016-07-26
CN104203976A (zh) 2014-12-10
SG11201405087PA (en) 2014-09-26
WO2013130981A1 (en) 2013-09-06
AU2013203942A8 (en) 2016-08-11
JP2018029625A (ja) 2018-03-01
MX2014010527A (es) 2014-10-14
CA2863536A1 (en) 2013-09-06
BR112014021251A2 (pt) 2017-06-27
RU2628305C2 (ru) 2017-08-15
US20130230531A1 (en) 2013-09-05
KR20140130709A (ko) 2014-11-11
UY34652A (es) 2013-09-02
RU2014139552A (ru) 2016-04-20
SG10201610123UA (en) 2017-01-27
CN108101983A (zh) 2018-06-01
AU2016203511A1 (en) 2016-06-16
JP2015509962A (ja) 2015-04-02
EP2820044A1 (en) 2015-01-07
AU2013203942B2 (en) 2016-03-10
NZ628943A (en) 2016-08-26

Similar Documents

Publication Publication Date Title
AR090219A1 (es) Anticuerpos humanos frente a toxinas de clostridium difficile
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CL2014000491A1 (es) Anticuerpos monoclonales neutralizantes de las exotoxinas tcda y/o tcdb de clostridium difficile; composición farmacéutica que los comprende; y uso para tratar infección por c. difficile.
CO2017013398A2 (es) Anticuerpos anti-ctla-4
BR112017003582A2 (pt) anticorpos, composições e usos
SV2017005424A (es) Métodos para tratar infecciones por el virus filoviridae
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
CO2019006902A2 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
UY34327A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan 4-hidrofenil-piruvato-dioxigenasa?.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
PE20141821A1 (es) Composiciones herbicidas que contienen bentazon y el inhibidor als y el inhibidor accasa
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112015010360A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma
AR089993A1 (es) Macrociclos peptidomimeticos
TR201817932T4 (tr) Staphylococcus aureus alfa toksi̇ni̇ni̇ spesi̇fi̇k olarak bağlayan anti̇korlar ve kullanim yöntemleri̇
EA201590766A1 (ru) Способы и композиции для лечения и контроля заболевания растений
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
EA201400447A1 (ru) АНТИТЕЛА К CD1d
GT201800102A (es) Polipéptidos que inhiben cd4ol

Legal Events

Date Code Title Description
FB Suspension of granting procedure